Table 1 Baseline characteristics of patients randomised to the three groups
Control | Home | Community | |
|---|---|---|---|
(n = 138) | (n = 134) | (n = 137) | |
Age (years) | 55.3 (10.5) | 54.6 (11.2) | 54.0 (9.2) |
BMI (kg/m²) | 27.6 (6.1) | 26.9 (4.8) | 27.0 (5.1) |
BMI Category | |||
Normal weight (18.5–24.99 kg/m2) | 58 (42.0%) | 50 (37.3%) | 55 (40.1%) |
Overweight (≥ 25–29.99 kg/m2) | 38 (27.5%) | 56 (41.8%) | 49 (35.8%) |
Obese (≥ 30 kg/m2) | 42 (30.4%) | 28 (20.9%) | 33 (24.1%) |
Pre/peri-menopausal | 56 (40.6%) | 55 (41.0%) | 49 (35.8%) |
Post-menopausal | 82 (59.4%) | 79 (59.0%) | 88 (64.2%) |
Days between final breast surgery and randomisation | 50 (39–68) | 55 (36–66) | 54 (40–68) |
Current smoker | 15 (10.9%) | 17 (12.7%) | 9 (6.6%) |
Ethnicity | |||
White | 132 (95.7%) | 126 (94.0%) | 129 (94.2%) |
Black | 2 (1.4%) | 4 (3.0%) | 4 (2.9%) |
Asian | 3 (2.2%) | 4 (3.0%) | 3 (2.2%) |
Mixed | 1 (0.7%) | 0 (0.0%) | 1 (0.7%) |
Social circumstances | |||
Married or cohabiting | 106 (76.8%) | 94 (70.0%) | 102 (74.5%) |
Educated to degree level or higher | 64 (46%) | 59 (44%) | 67 (49%) |
Index of multiple deprivation | |||
Greater Manchester Quintile | |||
1 (least deprived) | 66 (47.8%) | 46 (34.3%) | 48 (35.0%) |
2 | 28 (20.3%) | 31 (23.1%) | 31 (22.6%) |
3 | 15 (10.9%) | 26 (19.4%) | 24 (17.5%) |
4 | 12 (8.7%) | 15 (11.2%) | 17 (12.4%) |
5 (most deprived) | 17 (12.3%) | 16 (11.9%) | 17 (12.4%) |
Co-morbidities | |||
Respiratory, e.g. asthma, COPD | 19 (13.8%) | 15 (11.2%) | 15 (10.9%) |
Psychiatric, e.g. anxiety, depression | 14 (10.1%) | 16 (11.9%) | 19 (13.9%) |
Cardiovascular disease | 12 (8.6%) | 10 (7.4%) | 11 (8.0%) |
Arthritis, back or joint problems | 41 (29.0%) | 32 (24.0%) | 29 (21.6%) |
Type 2 diabetes | 3 (2.2%) | 7 (5.2%) | 4 (2.9%) |
Previous breast cancer | 8 (5.8%) | 7 (5.2%) | 3 (2.2%) |
Tumour characteristics | |||
DCIS/LCIS | 13 (9.4%) | 18 (13.4%) | 18 (13.2%) |
Invasive tumour Grade 1 | 25 (18.0%) | 23 (17.2%) | 21 (15.3%) |
Invasive tumour Grade 2 | 61 (44.2%) | 56 (41.8%) | 62 (45.3%) |
Invasive tumour Grade 3 | 40 (28.9%) | 38 (28.4%) | 34 (24.8%) |
Surgery | |||
Mastectomy | 45 (32.6%) | 47 (35.1%) | 48 (35.0%) |
Axillary node clearance (ANC) | 34 (24.6%) | 34 (25.4%) | 33 (24.1%) |
Screen detected breast cancer | 52 (51.0%) | 53 (54.6%) | 61 (60.4%) |
Adjuvant treatment a | |||
Chemotherapy | 52 (37.7%) | 52 (38.8%) | 51 (37.2%) |
Anthracycline only | 29 (21.0%) | 33 (24.6%) | 27 (20.0%) |
Anthracyline & taxane | 23 (16.7%) | 19 (14.2%) | 24 (17.5%) |
Radiotherapy | 98 (71.0%) | 91 (67.9%) | 104 (75.9%) |
Herceptin | 19 (13.8%) | 13 (9.7%) | 11 (8.0%) |
Tamoxifen | 68 (49.3%) | 75 (56.0%) | 78 (56.9%) |
Aromatase inhibitor | 36 (26.1%) | 34 (25.4%) | 34 (24.8%) |
No adjuvant treatment (no chemothetherapy, radiotherapy or other endocrine treatment) | 5 (3.6%) | 10 (7.5%) | 8 (5.8%) |
